PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34115925-3 2021 The utility of a flow score based on the five commonly used markers in leukaemia panels for T-ALL (CD34, CD8, CD5, CD13 and CD33) was evaluated to differentiate ETP from non-ETP-ALL. Ethionamide 161-164 CD34 molecule Homo sapiens 99-103 34396465-14 2022 Within the experimental groups, MPO activity was significantly reduced in the ETH (p = 0.04) and the ECLP (p < 0.01) groups compared with the 6CLP group. Ethionamide 78-81 myeloperoxidase Mus musculus 32-35 34474324-9 2021 Placental EtP levels were significantly associated with hypermethylation of cg08612779 annotated to GGT7 after correcting for multiple testing (ss = 0.0017, p = 0.049). Ethionamide 10-13 gamma-glutamyltransferase 7 Homo sapiens 100-104 34474324-12 2021 The association of placental EtP with cord blood GGT and glucose levels provides a starting point for further research on mechanisms of paraben-related metabolic processes in utero. Ethionamide 29-32 gamma-glutamyltransferase light chain family member 3 Homo sapiens 49-52 34115925-3 2021 The utility of a flow score based on the five commonly used markers in leukaemia panels for T-ALL (CD34, CD8, CD5, CD13 and CD33) was evaluated to differentiate ETP from non-ETP-ALL. Ethionamide 161-164 CD8a molecule Homo sapiens 105-108 34115925-3 2021 The utility of a flow score based on the five commonly used markers in leukaemia panels for T-ALL (CD34, CD8, CD5, CD13 and CD33) was evaluated to differentiate ETP from non-ETP-ALL. Ethionamide 161-164 CD5 molecule Homo sapiens 110-113 34115925-3 2021 The utility of a flow score based on the five commonly used markers in leukaemia panels for T-ALL (CD34, CD8, CD5, CD13 and CD33) was evaluated to differentiate ETP from non-ETP-ALL. Ethionamide 161-164 alanyl aminopeptidase, membrane Homo sapiens 115-119 34115925-3 2021 The utility of a flow score based on the five commonly used markers in leukaemia panels for T-ALL (CD34, CD8, CD5, CD13 and CD33) was evaluated to differentiate ETP from non-ETP-ALL. Ethionamide 161-164 CD33 molecule Homo sapiens 124-128 34824885-3 2021 Recent studies have identified a consistent expression of CD38 on the blasts of patients with T-ALL (both ETP-ALL and non ETP-ALL). Ethionamide 106-109 CD38 molecule Homo sapiens 58-62 34747732-9 2021 ETH resistance was detected among 87/108 (80.5%) isolates with inhA mutation. Ethionamide 0-3 inhibin subunit alpha Homo sapiens 63-67 34747732-10 2021 Sensitivity and specificity of inhA mutation for detection of ETH resistance were 80.5% and 83.8%, respectively. Ethionamide 62-65 inhibin subunit alpha Homo sapiens 31-35 34747732-12 2021 Conclusions: Mutations in inhA gene in LPA predict ETH resistance with fairly good sensitivity and specificity. Ethionamide 51-54 inhibin subunit alpha Homo sapiens 26-30 34747732-0 2021 Correlation of inhA mutations and ethionamide susceptibility: Experience from national reference center for tuberculosis. Ethionamide 34-45 inhibin subunit alpha Homo sapiens 15-19 34824885-3 2021 Recent studies have identified a consistent expression of CD38 on the blasts of patients with T-ALL (both ETP-ALL and non ETP-ALL). Ethionamide 122-125 CD38 molecule Homo sapiens 58-62 34815845-8 2021 The ETP-administered animals represented a significant reduction in AChE, TAC and catalase levels and remarkable increment in MDA content. Ethionamide 4-7 acetylcholinesterase Mus musculus 68-72 34402058-4 2021 A simplified three-marker (BCL11B, cluster of differentiation 5 (CD5), CD13) immunophenotypic score discriminated reliably between ETP-ALL and non-ETP-ALL/LBL. Ethionamide 131-134 alanyl aminopeptidase, membrane Homo sapiens 71-75 34402058-5 2021 In ETP-ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0 009). Ethionamide 3-6 BAF chromatin remodeling complex subunit BCL11B Homo sapiens 35-41 34815845-8 2021 The ETP-administered animals represented a significant reduction in AChE, TAC and catalase levels and remarkable increment in MDA content. Ethionamide 4-7 catalase Mus musculus 82-90 35478211-1 2022 This paper aimed to evaluate the role of oxidative stress in the regulation of ABC transporters in human lung cancer (A549) cells facing substrate (doxorubicin, DOX) and nonsubstrate (ethanol, ETH and hydrogen peroxide, HP) chemicals. Ethionamide 193-196 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 79-82 35505474-13 2022 The increase in low-level INH resistance mutation inhA-c-15t may be associated with ethionamide/prothionamide resistance, and this should be taken into account when designing DR-TB regimen. Ethionamide 84-95 inhibin subunit alpha Homo sapiens 50-54 35478211-5 2022 At moderate ROS levels (about 3-4-folds of control levels, caused by 10 muM DOX, 400 mM ETH, and 400 muM HP), all the three chemicals induced the gene expressions and activities of ABC transporters, but these values decreased at too high ROS levels (8.36-folds of control levels) caused by HP at LC50 (800 muM). Ethionamide 88-91 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 181-184 2529663-5 1989 PAI-1 activity showed the same level in all citrate based anticoagulants and ETP and no increase was found in blood standing for 2 hours at room temperature. Ethionamide 77-80 serpin family E member 1 Homo sapiens 0-5 35455983-14 2022 In the Eth group, the relative epididymal fat content, HDL-C level, and AST/ALT ratio were significantly decreased, and TG and gp91phox in liver were significantly higher than in the Sed group (p < 0.05, p < 0.01). Ethionamide 7-10 transmembrane protease, serine 11d Mus musculus 72-75 35455983-14 2022 In the Eth group, the relative epididymal fat content, HDL-C level, and AST/ALT ratio were significantly decreased, and TG and gp91phox in liver were significantly higher than in the Sed group (p < 0.05, p < 0.01). Ethionamide 7-10 glutamic pyruvic transaminase, soluble Mus musculus 76-79 35455983-14 2022 In the Eth group, the relative epididymal fat content, HDL-C level, and AST/ALT ratio were significantly decreased, and TG and gp91phox in liver were significantly higher than in the Sed group (p < 0.05, p < 0.01). Ethionamide 7-10 cytochrome b-245, beta polypeptide Mus musculus 127-135 35455983-15 2022 Compared with the Eth group, the AST/ALT ratio, MDA in the liver, and NOX4 and p47phox protein expression in the liver were significantly increased, and body weight decreased significantly in the Eth + Ex group (p < 0.05, p < 0.01), as did TG in the liver and MDA in muscle. Ethionamide 18-21 NADPH oxidase 4 Mus musculus 70-74 35455983-15 2022 Compared with the Eth group, the AST/ALT ratio, MDA in the liver, and NOX4 and p47phox protein expression in the liver were significantly increased, and body weight decreased significantly in the Eth + Ex group (p < 0.05, p < 0.01), as did TG in the liver and MDA in muscle. Ethionamide 196-199 transmembrane protease, serine 11d Mus musculus 33-36 35455983-15 2022 Compared with the Eth group, the AST/ALT ratio, MDA in the liver, and NOX4 and p47phox protein expression in the liver were significantly increased, and body weight decreased significantly in the Eth + Ex group (p < 0.05, p < 0.01), as did TG in the liver and MDA in muscle. Ethionamide 196-199 glutamic pyruvic transaminase, soluble Mus musculus 37-40 35455983-15 2022 Compared with the Eth group, the AST/ALT ratio, MDA in the liver, and NOX4 and p47phox protein expression in the liver were significantly increased, and body weight decreased significantly in the Eth + Ex group (p < 0.05, p < 0.01), as did TG in the liver and MDA in muscle. Ethionamide 196-199 NADPH oxidase 4 Mus musculus 70-74 35455983-17 2022 In the Eth + Ex + NOXI group, the ratio of AST/ALT and MDA in muscle were increased when compared with the Eth + Ex group, and the protein expression of gp91phox and p47phox were much lower (p < 0.01). Ethionamide 7-10 transmembrane protease, serine 11d Mus musculus 43-46 35455983-17 2022 In the Eth + Ex + NOXI group, the ratio of AST/ALT and MDA in muscle were increased when compared with the Eth + Ex group, and the protein expression of gp91phox and p47phox were much lower (p < 0.01). Ethionamide 7-10 glutamic pyruvic transaminase, soluble Mus musculus 47-50 35455983-17 2022 In the Eth + Ex + NOXI group, the ratio of AST/ALT and MDA in muscle were increased when compared with the Eth + Ex group, and the protein expression of gp91phox and p47phox were much lower (p < 0.01). Ethionamide 7-10 cytochrome b-245, beta polypeptide Mus musculus 153-161 35455983-17 2022 In the Eth + Ex + NOXI group, the ratio of AST/ALT and MDA in muscle were increased when compared with the Eth + Ex group, and the protein expression of gp91phox and p47phox were much lower (p < 0.01). Ethionamide 7-10 neutrophil cytosolic factor 1 Mus musculus 166-173 35455983-17 2022 In the Eth + Ex + NOXI group, the ratio of AST/ALT and MDA in muscle were increased when compared with the Eth + Ex group, and the protein expression of gp91phox and p47phox were much lower (p < 0.01). Ethionamide 107-110 cytochrome b-245, beta polypeptide Mus musculus 153-161 4963957-0 1966 [On the inhibition of catalase activity by 2-ethyl-isonicotinic acid thioamide]. Ethionamide 43-78 catalase Homo sapiens 22-30 6418158-3 1983 Haemoglobin augments also the lipoxygenase-induced loss of acid-labile sulphur in ETP not related to respiratory inhibition. Ethionamide 82-85 linoleate 9S-lipoxygenase-4 Glycine max 30-42 32835438-3 2021 In vitro assays using a biosynthetic precursor from a blocked mutant showed that GliF is specific to ETPs and catalyzes an unprecedented heterocyclization reaction that cannot be emulated with current synthetic methods. Ethionamide 101-105 macrophage migration inhibitory factor Homo sapiens 81-85 33662521-6 2021 RESULTS: In the HF+Eth diet, constitutively hepatic human COX-2 expression protects mice from body weight gain and white adipose tissue accumulation, accompanied by improved IPGTT response, serum triglyceride/cholesterol levels, and lower levels of serum and liver inflammatory cytokines. Ethionamide 19-22 prostaglandin-endoperoxide synthase 2 Mus musculus 58-63 33662521-8 2021 Hepatic hCOX-2 overexpression enhanced AKT insulin signaling and increased fatty acid synthesis in both RCD and HF+Eth diet groups. Ethionamide 115-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-14 33662521-9 2021 The anti-lipogenic effect of hCOX-2 TG in the HF+Eth diet animals was mediated by increasing lipid disposal through enhanced beta-oxidation via elevations in the expression of PPARalpha and PPARgamma, and increased hepatic autophagy as assessed by the ratio of autophagy markers LC3 II/I in hepatic tissue. Ethionamide 49-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-35 33662521-9 2021 The anti-lipogenic effect of hCOX-2 TG in the HF+Eth diet animals was mediated by increasing lipid disposal through enhanced beta-oxidation via elevations in the expression of PPARalpha and PPARgamma, and increased hepatic autophagy as assessed by the ratio of autophagy markers LC3 II/I in hepatic tissue. Ethionamide 49-52 peroxisome proliferator activated receptor alpha Mus musculus 176-185 33662521-10 2021 Various protein acetylation pathway components, including HAT, HDAC1, SIRT1, and SNAIL1, were modulated in hCOX-2 TG mice in either RCD or HF+Eth diet. Ethionamide 142-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-113 33420893-12 2021 In contrast, levels of IFN-gamma were significantly reduced in groups ETH and 6CLP compared with control group 1 (control 1: 8.92 pg./ml +- 4.38 vs. ETH: 1.77 pg./ml +- 4.34, p = 0.026 resp. vs. 6CLP: 1.83 pg./ml +- 4.49, p = 0.014). Ethionamide 70-73 interferon gamma Mus musculus 23-32 33420893-12 2021 In contrast, levels of IFN-gamma were significantly reduced in groups ETH and 6CLP compared with control group 1 (control 1: 8.92 pg./ml +- 4.38 vs. ETH: 1.77 pg./ml +- 4.34, p = 0.026 resp. vs. 6CLP: 1.83 pg./ml +- 4.49, p = 0.014). Ethionamide 149-152 interferon gamma Mus musculus 23-32 33420893-14 2021 Reduced MPO activity was lowest in group ECLP (ECLP 11,196.77 +- 547.81 vs. ETH 12,773.94 +- 1011.76; p = 0.023 resp. vs. 6CLP 13,155.19 +- 423.99, p = 0.016) in experimental groups. Ethionamide 76-79 myeloperoxidase Mus musculus 8-11 4387664-2 1968 On the influence of ethionamide on the endogenous metabolism of Myc. Ethionamide 20-31 MYC proto-oncogene, bHLH transcription factor Homo sapiens 64-67 33314736-9 2021 The sensitivity of the FibWave was similar to the one of the ETP-based APC resistance assay. Ethionamide 61-64 APC regulator of WNT signaling pathway Homo sapiens 71-74 33512434-8 2021 Corroborating our cell line data, Rasgrp1 haploinsufficiency induced Rasgrp1 downregulation, increased pERK level, and ETP expansion in NrasQ61R/+ mice. Ethionamide 119-122 RAS guanyl releasing protein 1 Mus musculus 34-41 33314736-11 2021 The FW-Max1 , FW-Max2, and to a lesser degree FW-Min2 were identified as the most sensitive parameters with a similar performance to the ETP-based APC resistance assay. Ethionamide 137-140 APC regulator of WNT signaling pathway Homo sapiens 147-150 32977637-5 2020 Preconditioning with ethionamide promoted the proliferation of Wharton"s jelly-derived MSCs (WJ-MSCs) by activating phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling. Ethionamide 21-32 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 116-145 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 4-13 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 15-18 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 CD80 antigen Mus musculus 86-90 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 CD86 antigen Mus musculus 92-96 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 tumor necrosis factor Mus musculus 143-152 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 interleukin 2 Mus musculus 154-158 32763432-5 2020 The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6. Ethionamide 27-30 interleukin 6 Mus musculus 163-167 32763432-6 2020 Subsequently, a novel OVA@Eth-HA-GC-loaded silk fibroin (OVA@Eth-HA-GC/SF) nanofibrous mats were fabricated through green electrospinning. Ethionamide 26-29 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 22-25 32763432-6 2020 Subsequently, a novel OVA@Eth-HA-GC-loaded silk fibroin (OVA@Eth-HA-GC/SF) nanofibrous mats were fabricated through green electrospinning. Ethionamide 61-64 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 22-25 32763432-8 2020 Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo. Ethionamide 36-39 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 32-35 32763432-8 2020 Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo. Ethionamide 36-39 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 77-80 32763432-8 2020 Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo. Ethionamide 36-39 interferon gamma Mus musculus 126-135 32763432-8 2020 Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo. Ethionamide 36-39 interleukin 2 Mus musculus 137-141 32763432-8 2020 Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo. Ethionamide 36-39 interleukin 6 Mus musculus 146-150 32977637-5 2020 Preconditioning with ethionamide promoted the proliferation of Wharton"s jelly-derived MSCs (WJ-MSCs) by activating phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling. Ethionamide 21-32 AKT serine/threonine kinase 1 Homo sapiens 153-156 32977637-5 2020 Preconditioning with ethionamide promoted the proliferation of Wharton"s jelly-derived MSCs (WJ-MSCs) by activating phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling. Ethionamide 21-32 mitogen-activated protein kinase kinase 7 Homo sapiens 248-251 32977637-5 2020 Preconditioning with ethionamide promoted the proliferation of Wharton"s jelly-derived MSCs (WJ-MSCs) by activating phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling. Ethionamide 21-32 mitogen-activated protein kinase 3 Homo sapiens 253-299 32977637-6 2020 Preconditioning with ethionamide also enhanced the migration ability of MSCs by upregulating expression of genes associated with migration, such as C-X-C motif chemokine receptor 4 (CXCR4) and C-X-C motif chemokine ligand 12 (CXCL12). Ethionamide 21-32 C-X-C motif chemokine receptor 4 Homo sapiens 148-180 32977637-6 2020 Preconditioning with ethionamide also enhanced the migration ability of MSCs by upregulating expression of genes associated with migration, such as C-X-C motif chemokine receptor 4 (CXCR4) and C-X-C motif chemokine ligand 12 (CXCL12). Ethionamide 21-32 C-X-C motif chemokine receptor 4 Homo sapiens 182-187 32977637-6 2020 Preconditioning with ethionamide also enhanced the migration ability of MSCs by upregulating expression of genes associated with migration, such as C-X-C motif chemokine receptor 4 (CXCR4) and C-X-C motif chemokine ligand 12 (CXCL12). Ethionamide 21-32 C-X-C motif chemokine ligand 12 Homo sapiens 193-224 32977637-6 2020 Preconditioning with ethionamide also enhanced the migration ability of MSCs by upregulating expression of genes associated with migration, such as C-X-C motif chemokine receptor 4 (CXCR4) and C-X-C motif chemokine ligand 12 (CXCL12). Ethionamide 21-32 C-X-C motif chemokine ligand 12 Homo sapiens 226-232 32319376-8 2020 The positive rate of CD56 in near-ETP group was 50%, which was significantly higher than that in ETP group (16.7%) and non-ETP group (0%) (P<0.01). Ethionamide 34-37 neural cell adhesion molecule 1 Homo sapiens 21-25 32319376-8 2020 The positive rate of CD56 in near-ETP group was 50%, which was significantly higher than that in ETP group (16.7%) and non-ETP group (0%) (P<0.01). Ethionamide 97-100 neural cell adhesion molecule 1 Homo sapiens 21-25 32319376-7 2020 The positive rates of CD4 and CD3 in non-ETP group were significantly higher than those in ETP and near-ETP group (P<0.01). Ethionamide 41-44 CD4 molecule Homo sapiens 22-25 32319376-8 2020 The positive rate of CD56 in near-ETP group was 50%, which was significantly higher than that in ETP group (16.7%) and non-ETP group (0%) (P<0.01). Ethionamide 97-100 neural cell adhesion molecule 1 Homo sapiens 21-25 30690726-0 2019 Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. Ethionamide 95-106 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 151-155 30690726-7 2019 Compared to the wild type, recombinant Lys158 -FMO3 and Gly308 -FMO3 variants significantly decreased the intrinsic clearance of ethionamide by 2% and 24%, respectively. Ethionamide 129-140 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 64-68 31635590-4 2019 The katG and inhA genes are associated with high- and low-level INH resistance, respectively, as well as cross-resistance to ethionamide in the case of inhA gene mutations. Ethionamide 125-136 inhibin subunit alpha Homo sapiens 13-17 31635590-4 2019 The katG and inhA genes are associated with high- and low-level INH resistance, respectively, as well as cross-resistance to ethionamide in the case of inhA gene mutations. Ethionamide 125-136 inhibin subunit alpha Homo sapiens 152-156 31635590-5 2019 Patients with MDR-TB due to an inhA mutation could benefit from the use of high-dose INH - instead of ethionamide - in their MDR-TB regimen. Ethionamide 102-113 inhibin subunit alpha Homo sapiens 31-35 30848403-11 2019 Conclusions ETP therapy showed acceptable efficacy and safety and is a potential first-line therapy for patients with HER2-positive MBC. Ethionamide 12-15 erb-b2 receptor tyrosine kinase 2 Homo sapiens 118-122 30690726-8 2019 Two prevalent functional variants of FMO3 were predicted to affect ethionamide disposition, with mean ratios of Cmax and AUC of up to 1.5 and 1.7, respectively, in comparison with the wild type. Ethionamide 67-78 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 37-41 30690726-9 2019 In comparing single ethionamide administration with the wild type, simulations of the combined effects of comedications and FMO3 genetic polymorphism estimated that the Cmax and AUC ratios of ethionamide increased up to 1.7 and 2.0, respectively. Ethionamide 20-31 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 124-128 30690726-2 2019 We previously reported the major contribution of flavin-containing monooxygenase 3 (FMO3) in the reductive elimination pathway of ethionamide. Ethionamide 130-141 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 49-82 30690726-9 2019 In comparing single ethionamide administration with the wild type, simulations of the combined effects of comedications and FMO3 genetic polymorphism estimated that the Cmax and AUC ratios of ethionamide increased up to 1.7 and 2.0, respectively. Ethionamide 192-203 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 124-128 30690726-2 2019 We previously reported the major contribution of flavin-containing monooxygenase 3 (FMO3) in the reductive elimination pathway of ethionamide. Ethionamide 130-141 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 84-88 30690726-10 2019 These findings suggested that FMO3-mediated drug-drug interaction and genetic polymorphism could be important determinants of interindividual heterogeneity in ethionamide disposition that need to be considered comprehensively to optimize the personalized dosing of ethionamide. Ethionamide 159-170 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 30-34 30690726-10 2019 These findings suggested that FMO3-mediated drug-drug interaction and genetic polymorphism could be important determinants of interindividual heterogeneity in ethionamide disposition that need to be considered comprehensively to optimize the personalized dosing of ethionamide. Ethionamide 265-276 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 30-34 30690726-4 2019 The drug-drug interaction leading to methimazole affecting the disposition of ethionamide mediated by FMO3 was then quantitated using a bottom-up approach with a physiologically based pharmacokinetic framework. Ethionamide 78-89 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 102-106 30690726-7 2019 Compared to the wild type, recombinant Lys158 -FMO3 and Gly308 -FMO3 variants significantly decreased the intrinsic clearance of ethionamide by 2% and 24%, respectively. Ethionamide 129-140 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 47-51 29878384-0 2018 Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavin-Containing Monooxygenase 3 Maturational Changes Over Time. Ethionamide 64-75 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 119-152 30684598-2 2019 Solubilities of moxifloxacin and ethionamide in phosphate buffered saline (PBS, pH 7.4) were 17.68 +- 0.85 mg mL-1 and 0.46 +- 0.02 mg mL-1 whereas in the presence of lung surfactant (0.4% w/v Curosurf in PBS) solubilities were 20.76 +- 0.35 mg mL-1 and 0.56 +- 0.03 mg mL-1, respectively. Ethionamide 33-44 L1 cell adhesion molecule Mus musculus 110-114 30684598-2 2019 Solubilities of moxifloxacin and ethionamide in phosphate buffered saline (PBS, pH 7.4) were 17.68 +- 0.85 mg mL-1 and 0.46 +- 0.02 mg mL-1 whereas in the presence of lung surfactant (0.4% w/v Curosurf in PBS) solubilities were 20.76 +- 0.35 mg mL-1 and 0.56 +- 0.03 mg mL-1, respectively. Ethionamide 33-44 L1 cell adhesion molecule Mus musculus 135-139 30684598-2 2019 Solubilities of moxifloxacin and ethionamide in phosphate buffered saline (PBS, pH 7.4) were 17.68 +- 0.85 mg mL-1 and 0.46 +- 0.02 mg mL-1 whereas in the presence of lung surfactant (0.4% w/v Curosurf in PBS) solubilities were 20.76 +- 0.35 mg mL-1 and 0.56 +- 0.03 mg mL-1, respectively. Ethionamide 33-44 L1 cell adhesion molecule Mus musculus 135-139 30684598-2 2019 Solubilities of moxifloxacin and ethionamide in phosphate buffered saline (PBS, pH 7.4) were 17.68 +- 0.85 mg mL-1 and 0.46 +- 0.02 mg mL-1 whereas in the presence of lung surfactant (0.4% w/v Curosurf in PBS) solubilities were 20.76 +- 0.35 mg mL-1 and 0.56 +- 0.03 mg mL-1, respectively. Ethionamide 33-44 L1 cell adhesion molecule Mus musculus 135-139 29878384-5 2018 We hypothesized that the age-dependent changes in ethionamide elimination were predominantly a result of the progressive increases in the expression and metabolic capacity of FMO3 during childhood. Ethionamide 50-61 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 175-179 29878384-7 2018 Thus, a good prediction PBPK model was validated successfully both in adults and children and applied to demonstrate the critical contribution of FMO3 in the mechanistic elimination pathway of ethionamide. Ethionamide 193-204 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 146-150 29067094-3 2017 The NUP214-ABL1 gene is present in ~6% of T-ALL cases, however the prevalence of NUP214-ABL1 gene expression in ETP-ALL in particular has not yet been verified. Ethionamide 112-115 nucleoporin 214 Homo sapiens 81-87 28819071-1 2017 Hepatic flavin-containing mono-oxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine). Ethionamide 221-232 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 0-42 28819071-1 2017 Hepatic flavin-containing mono-oxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine). Ethionamide 221-232 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 44-48 29067094-3 2017 The NUP214-ABL1 gene is present in ~6% of T-ALL cases, however the prevalence of NUP214-ABL1 gene expression in ETP-ALL in particular has not yet been verified. Ethionamide 112-115 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 88-92 28957755-0 2017 Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA). Ethionamide 80-91 inhibin subunit alpha Homo sapiens 132-136 26544630-0 2015 Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. Ethionamide 13-24 tyrosinase Mus musculus 105-115 28043598-5 2016 Nicotinamide adenine dinucleotide is coded by the ndh gene, and its overexpresion may lead cross-resistance between INH and ETH drugs. Ethionamide 124-127 GLIS family zinc finger 3 Homo sapiens 50-53 28043598-26 2016 Unfavorable treatment outcomes of patients with ethA, ethR, and inhA mutations highlight the importance of genotypic testing before initiation of treatment containing ETH. Ethionamide 167-170 sodium voltage-gated channel alpha subunit 9 Homo sapiens 48-52 28043598-26 2016 Unfavorable treatment outcomes of patients with ethA, ethR, and inhA mutations highlight the importance of genotypic testing before initiation of treatment containing ETH. Ethionamide 167-170 inhibin subunit alpha Homo sapiens 64-68 26586461-7 2016 Thrombin-generation parameters, such as the area under the curve (referred to as ETP), peak-thrombin, and velocity-index, when measured after addition of thrombomodulin, showed unexpected changes: ETP decreased, but peak-thrombin and velocity-index increased. Ethionamide 81-84 coagulation factor II, thrombin Homo sapiens 0-8 27393546-0 2016 Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Ethionamide 60-71 inhibin subunit alpha Homo sapiens 22-26 27393546-1 2016 BACKGROUND: Depending on the presence of mutations that determine isoniazid (INH) susceptibility (katG and inhA), Mycobacterium tuberculosis may be susceptible to high doses of INH or ethionamide (ETH). Ethionamide 184-195 inhibin subunit alpha Homo sapiens 107-111 26586647-2 2016 ETH and PTH are pro-drugs that, following enzymatic activation by mycobacterial EthA inhibit InhA, a target shared with isoniazid (INH), and subsequently inhibit mycolic acid synthesis of Mycobacterium tuberculosis. Ethionamide 0-3 sodium voltage-gated channel alpha subunit 9 Homo sapiens 80-84 26586647-2 2016 ETH and PTH are pro-drugs that, following enzymatic activation by mycobacterial EthA inhibit InhA, a target shared with isoniazid (INH), and subsequently inhibit mycolic acid synthesis of Mycobacterium tuberculosis. Ethionamide 0-3 inhibin subunit alpha Homo sapiens 93-97 26586647-3 2016 Co-resistance to INH and ETH is conferred by mutations in the mycobacterial inhA promoter region; mutations in the ethA gene often underlie ETH and PTH monoresistance. Ethionamide 25-28 inhibin subunit alpha Homo sapiens 76-80 26586647-3 2016 Co-resistance to INH and ETH is conferred by mutations in the mycobacterial inhA promoter region; mutations in the ethA gene often underlie ETH and PTH monoresistance. Ethionamide 140-143 sodium voltage-gated channel alpha subunit 9 Homo sapiens 115-119 26708503-3 2016 Using an ARE-luciferase reporter expressed in several human and mouse cells, we identified a set of compounds, including isonicotinic acid amides, isoniazid and ethionamide, that inhibited NRF2-ARE activity. Ethionamide 161-172 nuclear factor, erythroid derived 2, like 2 Mus musculus 189-193 26708503-4 2016 Treatment of THP-1 cells with ethionamide, for instance, significantly reduced mRNA expression of multiple ARE-driven genes under either basal or As2O3-challenged conditions. Ethionamide 30-41 GLI family zinc finger 2 Homo sapiens 13-18 26708503-5 2016 As determined by cell viability and cell cycle, suppression of NRF2-ARE by ethionamide also significantly enhanced susceptibility of THP-1 and U937 cells to As2O3-induced cytotoxicity. Ethionamide 75-86 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 26708503-5 2016 As determined by cell viability and cell cycle, suppression of NRF2-ARE by ethionamide also significantly enhanced susceptibility of THP-1 and U937 cells to As2O3-induced cytotoxicity. Ethionamide 75-86 GLI family zinc finger 2 Homo sapiens 133-138 26708503-6 2016 In THP-1 cells, the sensitizing effect of ethionamide on As2O3-induced cytotoxicity was highly dependent on NRF2. Ethionamide 42-53 GLI family zinc finger 2 Homo sapiens 3-8 26708503-6 2016 In THP-1 cells, the sensitizing effect of ethionamide on As2O3-induced cytotoxicity was highly dependent on NRF2. Ethionamide 42-53 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 26708503-7 2016 To our knowledge, the present study is the first to demonstrate that ethionamide suppresses NRF2-ARE signaling and disrupts the transcriptional network of the antioxidant response in AML cells, leading to sensitization to chemotherapeutic agents. Ethionamide 69-80 NFE2 like bZIP transcription factor 2 Homo sapiens 92-96 26544630-3 2015 In this study, we report on the inhibition of tyrosinase by ethionamide and its analogues. Ethionamide 60-71 tyrosinase Mus musculus 46-56 26544630-5 2015 The chemical similarity of ethionamide to phenylthiourea, a well-known tyrosinase inhibitor, led us to investigate its inhibitory effects on mushroom tyrosinase and the IC50 was calculated as 4 muM. Ethionamide 27-38 tyrosinase Mus musculus 71-81 26544630-5 2015 The chemical similarity of ethionamide to phenylthiourea, a well-known tyrosinase inhibitor, led us to investigate its inhibitory effects on mushroom tyrosinase and the IC50 was calculated as 4 muM. Ethionamide 27-38 tyrosinase Mus musculus 150-160 26094899-3 2015 Isoniazid and clofazimine had inhibitory effects on four CYP reactions, and rifapentine, ethionamide, and prothionamide widely inhibited CYP reactions. Ethionamide 89-100 peptidylprolyl isomerase G Homo sapiens 137-140 26332235-3 2015 inhA mutations confer low-level resistance to isoniazid and cross-resistance to ethionamide while katG mutations confer high-level isoniazid resistance and no cross-resistance. Ethionamide 80-91 inhibin subunit alpha Homo sapiens 0-4 25767050-2 2015 Among them, G1 and G7 , dibenzyl tetramethylene bis-carbamate derivatives, are found to afford a novel stable pseudo[2]rotaxane with EtP[5]A, respectively, and G7 EtP[5]A shows photoresponsive properties. Ethionamide 133-136 proline rich protein BstNI subfamily 3 Homo sapiens 12-21 25767050-2 2015 Among them, G1 and G7 , dibenzyl tetramethylene bis-carbamate derivatives, are found to afford a novel stable pseudo[2]rotaxane with EtP[5]A, respectively, and G7 EtP[5]A shows photoresponsive properties. Ethionamide 165-168 proline rich protein BstNI subfamily 3 Homo sapiens 12-21 27148573-4 2015 The three gain-of-function mutations were absent from remission marrow cells, but the DNMT3A mutation persisted in heterozygous form in remission marrow, consistent with an origin for the patient"s ETP-ALL from clonal hematopoiesis. Ethionamide 198-201 DNA methyltransferase 3 alpha Homo sapiens 86-92 27148573-7 2015 H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. Ethionamide 172-175 MYC proto-oncogene, bHLH transcription factor Homo sapiens 39-42 27148573-7 2015 H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. Ethionamide 172-175 bromodomain containing 4 Homo sapiens 133-137 27148573-7 2015 H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. Ethionamide 172-175 MYC proto-oncogene, bHLH transcription factor Homo sapiens 201-204 27148573-7 2015 H3K27ac super-enhancer landscapes near MYC showed a pattern previously reported in acute myeloid leukemia (AML) that is sensitive to BRD4 inhibitors, and in line with this ETP-ALL blasts downregulated MYC in response to the BRD4 inhibitor JQ1. Ethionamide 172-175 bromodomain containing 4 Homo sapiens 224-228 25048293-1 2014 Hydride complexes Mo,W(CO)(NO)H(mer-etp(i)p) (iPr2PCH2CH2)2PPh=etp(i)p) (2 a,b(syn), syn and anti of NO and Ph(etp(i)p) orientions) were prepared and probed in imine hydrogenations together with co-catalytic [H(Et2O)2][B(C6F5)4] (140 C, 60 bar H2). Ethionamide 36-39 synemin Homo sapiens 79-82 25048293-1 2014 Hydride complexes Mo,W(CO)(NO)H(mer-etp(i)p) (iPr2PCH2CH2)2PPh=etp(i)p) (2 a,b(syn), syn and anti of NO and Ph(etp(i)p) orientions) were prepared and probed in imine hydrogenations together with co-catalytic [H(Et2O)2][B(C6F5)4] (140 C, 60 bar H2). Ethionamide 63-66 synemin Homo sapiens 79-82 25048293-1 2014 Hydride complexes Mo,W(CO)(NO)H(mer-etp(i)p) (iPr2PCH2CH2)2PPh=etp(i)p) (2 a,b(syn), syn and anti of NO and Ph(etp(i)p) orientions) were prepared and probed in imine hydrogenations together with co-catalytic [H(Et2O)2][B(C6F5)4] (140 C, 60 bar H2). Ethionamide 63-66 synemin Homo sapiens 85-88 24329989-7 2014 ETP- and pre-T-ALL together (CD1a(-) ,CD5(-/+) immature T-ALL group) were nearly always M/S(+) (29/31; 93.55%). Ethionamide 0-3 CD1a molecule Homo sapiens 29-33 24708207-2 2014 After a median follow-up of 4 years and 10 months, the ETP sub-group, representing 16% of T-ALL patients, had non-significantly inferior 5-year event-free survival (76 7% vs. 84 6%, P = 0 2) and overall survival (82 4% vs. 90 9%, P = 0 1), and a higher relapse rate (18 6% vs. 9 6%, P = 0 1) compared to typical T-ALL. Ethionamide 55-58 tumor protein, translationally-controlled 1 Homo sapiens 182-189 25199009-9 2014 Mutations in the inhA region were rare, which shows its minimal contribution to the development of resistance to ethionamide. Ethionamide 113-124 inhibin subunit alpha Homo sapiens 17-21 24566628-4 2014 While most studies have focused on the role of EthA-EthR in ETH bioactivation, its physiological role in mycobacteria has remained elusive, although a role in bacterial cell detoxification has been proposed. Ethionamide 60-63 sodium voltage-gated channel alpha subunit 9 Homo sapiens 47-51 25269127-5 2014 In the first year of operation, the MTP/ETP was activated five times on five separate patients. Ethionamide 40-43 metallothionein 1B Homo sapiens 36-39 24687960-3 2014 We show that activating mutations in the interleukin-7 receptor identified in human pediatric ETP-ALL cases are sufficient to generate ETP-ALL in mice transplanted with primitive transduced thymocytes from p19(Arf-/-) mice. Ethionamide 94-97 interleukin 7 receptor Homo sapiens 41-63 24687960-3 2014 We show that activating mutations in the interleukin-7 receptor identified in human pediatric ETP-ALL cases are sufficient to generate ETP-ALL in mice transplanted with primitive transduced thymocytes from p19(Arf-/-) mice. Ethionamide 94-97 interleukin 23, alpha subunit p19 Mus musculus 206-209 24687960-3 2014 We show that activating mutations in the interleukin-7 receptor identified in human pediatric ETP-ALL cases are sufficient to generate ETP-ALL in mice transplanted with primitive transduced thymocytes from p19(Arf-/-) mice. Ethionamide 135-138 interleukin 7 receptor Homo sapiens 41-63 24687960-3 2014 We show that activating mutations in the interleukin-7 receptor identified in human pediatric ETP-ALL cases are sufficient to generate ETP-ALL in mice transplanted with primitive transduced thymocytes from p19(Arf-/-) mice. Ethionamide 135-138 interleukin 23, alpha subunit p19 Mus musculus 206-209 24329989-7 2014 ETP- and pre-T-ALL together (CD1a(-) ,CD5(-/+) immature T-ALL group) were nearly always M/S(+) (29/31; 93.55%). Ethionamide 0-3 CD5 molecule Homo sapiens 38-41 24192167-4 2013 As a prodrug, ethionamide is bioactivated by EthA, a mono-oxygenase whose activity is repressed by EthR, a member of the TetR family of regulators. Ethionamide 14-25 sodium voltage-gated channel alpha subunit 9 Homo sapiens 45-49 24247125-7 2014 In the 25 patients enrolled on a regimen of kanamycin, levofloxacin, ethionamide, pyrazinamide, and cycloserine, the C2 values were found to be below the expected range for levofloxacin in 13 (52%) and kanamycin in 10 (40%). Ethionamide 69-80 complement C2 Homo sapiens 117-119 23826181-4 2013 RESULTS: Although thrombin generation was slightly delayed in cases (lag time increased from 3.3 to 3.6 min) at the highest trigger, the overall potential to generate thrombin was increased by 7% for the ETP and by 15% for the peak height (both at the 1 pM TF trigger) in cases. Ethionamide 204-207 coagulation factor II, thrombin Homo sapiens 167-175 23926305-8 2013 Thus, the LMO2-LYL1 interaction is a promising therapeutic target for inhibiting self-renewing cancer stem cells in T-ALL, including poor-prognosis ETP-ALL cases. Ethionamide 148-151 LIM domain only 2 Homo sapiens 10-14 23926305-8 2013 Thus, the LMO2-LYL1 interaction is a promising therapeutic target for inhibiting self-renewing cancer stem cells in T-ALL, including poor-prognosis ETP-ALL cases. Ethionamide 148-151 LYL1 basic helix-loop-helix family member Homo sapiens 15-19 23826181-6 2013 Furthermore, an increased thrombin generation was associated with MI [normalized ETP: adjusted OR for the highest percentile = 2.4 (95% CI 1.3-4.5) and normalized peak height: adjusted OR = 2.6 (1.3-5.0)] at the lowest trigger; normalized ETP and peak height being 2.1 (1.1-3.8) and 2.0 (1.0-4.1) at the higher 2 pM trigger. Ethionamide 81-84 coagulation factor II, thrombin Homo sapiens 26-34 23352980-6 2013 After structure-based drug selection, SGI-1776, ETP-45299, and tryptanthrin were selected as candidates of PIM1 inhibitors that act as radiosensitizers. Ethionamide 48-51 proviral integration site 1 Mus musculus 107-111 23476046-7 2013 RESULTS: ETP increased in association with PM10 (beta=20.0, 95% CI 3.0 to 37.0), PM1 (beta=80.8 95% CI 14.9 to 146.7) and zinc (beta=51.3, 95% CI 0.01 to 111.1) exposures. Ethionamide 9-12 transmembrane protein 11 Homo sapiens 43-46 23476046-10 2013 Lower NOS3 (beta=-42.3; p<0.001) and EDN1 (beta=-14.5; p=0.05) were associated with higher ETP. Ethionamide 94-97 nitric oxide synthase 3 Homo sapiens 6-10 23476046-10 2013 Lower NOS3 (beta=-42.3; p<0.001) and EDN1 (beta=-14.5; p=0.05) were associated with higher ETP. Ethionamide 94-97 endothelin 1 Homo sapiens 40-44 23352980-13 2013 Taken together, our findings provided evidence that PIM1-specific inhibitors, SGI-1776, ETP-45299, and tryptanthrin, can act as novel radiosensitizers to enhance the efficacy of radiotherapy by inhibiting irradiation-induced signaling pathway associated with radioresistance. Ethionamide 88-91 proviral integration site 1 Mus musculus 52-56 22098589-3 2012 Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. Ethionamide 117-128 sodium voltage-gated channel alpha subunit 9 Homo sapiens 72-76 23146620-0 2013 Can inhA mutation predict ethionamide resistance? Ethionamide 26-37 inhibin subunit alpha Homo sapiens 4-8 23146620-2 2013 OBJECTIVE: To estimate the extent of association between inhA mutant isoniazid (INH) resistant strains and ethionamide (ETH) resistance. Ethionamide 107-118 inhibin subunit alpha Homo sapiens 57-61 23146620-2 2013 OBJECTIVE: To estimate the extent of association between inhA mutant isoniazid (INH) resistant strains and ethionamide (ETH) resistance. Ethionamide 120-123 inhibin subunit alpha Homo sapiens 57-61 23146620-5 2013 An inhA promoter mutation was identified in 24 (21.4%) INH-resistant isolates, 21 (87.5%) of which were ETH-resistant (P < 0.0001). Ethionamide 105-108 inhibin subunit alpha Homo sapiens 3-7 22520259-3 2012 ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Ethionamide 0-3 thymoma viral proto-oncogene 1 Mus musculus 64-67 22389470-4 2012 We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells. Ethionamide 119-122 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-54 22389470-4 2012 We found that human epidermal growth factor receptor 2 (HER2) expressions are also upregulated in chemoresistant SBC-3/ETP, SBC-3/SN-38, and SBC-3/CDDP cells, compared with chemosensitive SBC-3 cells. Ethionamide 119-122 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-60 19859963-9 2010 The observations reported here show phenotypic similarities between VM-TH(+) and ES-TH(+) neurons and suggest that semaphorins 3A and 3C could be employed to guide axons of grafted ES-TH(+) in therapeutic protocols for PD. Ethionamide 81-86 semaphorin 3A Homo sapiens 115-136 22026918-5 2011 Importantly, NudC(BCG) was found to degrade the active forms of isoniazid (INH), INH-NAD and ethionamide (ETH), ETH-NAD. Ethionamide 93-104 NADH pyrophosphatase Mycobacterium tuberculosis H37Rv 13-17 22026918-5 2011 Importantly, NudC(BCG) was found to degrade the active forms of isoniazid (INH), INH-NAD and ethionamide (ETH), ETH-NAD. Ethionamide 93-104 NAD(+) diphosphatase Mycolicibacterium smegmatis MC2 155 18-21 22026918-5 2011 Importantly, NudC(BCG) was found to degrade the active forms of isoniazid (INH), INH-NAD and ethionamide (ETH), ETH-NAD. Ethionamide 106-109 NADH pyrophosphatase Mycobacterium tuberculosis H37Rv 13-17 22026918-5 2011 Importantly, NudC(BCG) was found to degrade the active forms of isoniazid (INH), INH-NAD and ethionamide (ETH), ETH-NAD. Ethionamide 106-109 NAD(+) diphosphatase Mycolicibacterium smegmatis MC2 155 18-21 22026918-7 2011 Further genetic studies showed that deletion of the nudC gene in M. smegmatis mc(2)155 and M. bovis BCG resulted in increased susceptibility to INH and ETH. Ethionamide 152-155 NAD(+) diphosphatase Mycolicibacterium smegmatis MC2 155 52-56 22026918-7 2011 Further genetic studies showed that deletion of the nudC gene in M. smegmatis mc(2)155 and M. bovis BCG resulted in increased susceptibility to INH and ETH. Ethionamide 152-155 NAD(+) diphosphatase Mycolicibacterium smegmatis MC2 155 100-103 20863819-2 2011 Reactive intermediates produced in the EtaA-catalyzed transformations of ethionamide and prothionamide result in NAD(+)/NADH adducts that inhibit the enoyl CoA reductase InhA, the ultimate target of these drugs. Ethionamide 73-84 inhibin subunit alpha Homo sapiens 170-174 22035573-5 2012 In a multiple stepwise regression including all subjects, subcutaneous adipose tissue thickness of upper back, cholesterol and ultrasensitive C-reactive protein were the best predictors for ETP. Ethionamide 190-193 C-reactive protein Homo sapiens 142-160 12869355-8 2003 Prothrombin fragment 1+2 plasma levels were significantly higher after 6 months of treatment in women allocated to oral ERT compared with those on placebo and transdermal ERT and were positively and significantly correlated with changes in ETP-based APC sensitivity ratio. Ethionamide 240-243 APC regulator of WNT signaling pathway Homo sapiens 250-253 19861006-6 2009 An inhA promoter mutation was identified in 15 (33.3%); 12/14 (86%) of these isolates were also ETH-resistant. Ethionamide 96-99 inhibin subunit alpha Homo sapiens 3-7 19589782-4 2009 In support of both cell-based and animal work showing that the cytotoxic effect of ETPs is reduced by the addition of Zn(2+) through an unknown mechanism, our mechanistic studies reveal that ETPs react with p300, causing zinc ion ejection. Ethionamide 83-87 E1A binding protein p300 Homo sapiens 207-211 18930751-0 2008 Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Ethionamide 41-52 flavin containing dimethylaniline monoxygenase 1 Homo sapiens 72-76 18930751-0 2008 Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Ethionamide 41-52 flavin containing dimethylaniline monoxygenase 2 Homo sapiens 78-82 18930751-0 2008 Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Ethionamide 41-52 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 87-91 16895935-5 2006 RESULTS: Data indicated that the intracellular metabolization of ethionamide strictly depends on the presence of the monooxygenase EthA and that EthA-dependent activation of ethionamide is coupled to a precise molecular sorting mechanism of the ethionamide metabolites. Ethionamide 65-76 sodium voltage-gated channel alpha subunit 9 Homo sapiens 131-135 16895935-5 2006 RESULTS: Data indicated that the intracellular metabolization of ethionamide strictly depends on the presence of the monooxygenase EthA and that EthA-dependent activation of ethionamide is coupled to a precise molecular sorting mechanism of the ethionamide metabolites. Ethionamide 65-76 sodium voltage-gated channel alpha subunit 9 Homo sapiens 145-149 16895935-5 2006 RESULTS: Data indicated that the intracellular metabolization of ethionamide strictly depends on the presence of the monooxygenase EthA and that EthA-dependent activation of ethionamide is coupled to a precise molecular sorting mechanism of the ethionamide metabolites. Ethionamide 174-185 sodium voltage-gated channel alpha subunit 9 Homo sapiens 145-149 16895935-5 2006 RESULTS: Data indicated that the intracellular metabolization of ethionamide strictly depends on the presence of the monooxygenase EthA and that EthA-dependent activation of ethionamide is coupled to a precise molecular sorting mechanism of the ethionamide metabolites. Ethionamide 174-185 sodium voltage-gated channel alpha subunit 9 Homo sapiens 145-149 15528841-3 2004 In the current study, we examined the inhibitory effects of pyrazinamide and ethionamide, both of which are chemically related to isoniazid, on the CYP-mediated activities in human liver microsomes and compared them to that of isoniazid. Ethionamide 77-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 148-151 15236969-0 2004 Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. Ethionamide 98-109 tetracycline resistance repressor protein TetR Escherichia coli 25-29 15236969-2 2004 Activation of the pro-drug ethionamide is regulated by the Baeyer-Villiger monooxygenase EthA and the TetR/CamR family repressor EthR, whose open reading frames are separated by 75 bp on the Mycobacterium tuberculosis genome. Ethionamide 27-38 tetracycline resistance repressor protein TetR Escherichia coli 102-106 10625209-9 1999 Mean APC-sr in patients with DVT at the onset was significantly higher (3.57 +/- 0.54) than mean APC-sr during puerperium was, indicating that the sensitivity to APC was reduced in the ETP-based assay. Ethionamide 185-188 APC regulator of WNT signaling pathway Homo sapiens 5-8 12557715-0 2003 [A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)]. Ethionamide 141-144 serpin family B member 3 Homo sapiens 72-75